Global Acute Myeloid Leukemia (AML) Therapeutics Market Report 2023-2030: Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development
Thursday, December 14, 2023
DUBLIN, Dec. 6, 2023 /PRNewswire/ -- The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $1.6 Billion by 2030
The global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$587.6 Million in the year 2022, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. Cytarabine, one of the segments analyzed in the report, is projected to record 15.6% CAGR and reach US$571.6 Million by the end of the analysis period. Growth in the Anthracycline Drugs segment is estimated at 14.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $217.3 Million, While China is Forecast to Grow at 15.4% CAGR
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$217.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$151 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 12.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.
What`s New?
-- Special discussions on the global economic climate and market sentiment
-- Coverage on global competitiveness and key competitor percentage market
shares
-- Market presence analysis across multiple geographies -
Strong/Active/Niche/Trivial
-- Online interactive peer-to-peer collaborative bespoke updates
-- Access to digital archives and trademarked research platform
-- Complimentary updates for one year
-- Access to curated YouTube video transcripts of market sentiments shared
by CEOs, domain experts and market influencers via interviews, podcasts,
press statements and event keynotes
MARKET TRENDS & DRIVERS
-- High Incidence and Prevalence Drive Market Growth
-- Ballooning Elderly Population: The Vital Growth Driver for AML
Therapeutics
-- Expanding Elderly Population Worldwide: Breakdown of Number of People
Aged 65+ Years in Million by Geographic Region for the Years 2019 and
2030
-- Life Expectancy for Select Countries in Number of Years: 2019
-- Advancements in Pharmacology & Molecular Biology to Promote AML Drug
Development
-- Recent Drug Approvals
-- Rising Investments in AML Therapeutics R&D Augurs Well
-- Changing Face of Combination Therapies Improve Outcomes for treated
Secondary AML
-- University of Texas' Combination Therapy Study Shines Light at the end
of Tunnel for Acute Myeloid Leukemia
-- Need for Better Treatments Entrenches Proteomics at Center of Acute
Myeloid Leukemia Therapeutics R&D
-- Antibody-Oriented Protein Microarrays
-- AML - A Medical Challenge with High Relapse Rate
-- Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia
-- Advances Related to FLT3 Inhibitors
-- Gilteritinib to Set New Therapeutic Paradigm for Acute Myeloid Leukemia
-- Novel Combination Therapies for Relapsed or Refractory AML
-- Novel Therapies for Treatment of Pediatric Relapsed AML
-- Immunotherapy Research for AML
-- Monoclonal Antibody (Mylotarg) - A Promising Drug
-- Chemotherapy Complications to Hinder the AML Market Growth
MARKET OVERVIEW
COVID-19 IMPACT AND THE LOOMING RECESSION
-- COVID-19's Impact on Cancer Patients
-- Making the Cancer Patient Survive the Lethal Covid-19 Wave
-- Post-Covid-19 Complications to Affect Future Cancer Treatment
-- The Evolving Model of Care - Virtual/ Telemedicine Consultations
-- The Evolving Model of Care - Extending Care through Innovative Means
-- Pandemic Causes Delays in Procedures and Treatment
-- In-Office Cancer Patient Visits Decline amidst Pandemic
-- Vaccine Availability Comforts Cancer Patients
COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS
-- Pandemic Caused Delays Impact AML Patients
-- Pandemic Related Issues Affect Oncology Research
-- Competition
-- Competitive Market Presence - Strong/Active/Niche/Trivial for Players
Worldwide in 2022 (E)
-- Acute Myeloid Leukemia (AML) Therapeutics - Global Key Competitors
Percentage Market Share in 2022 (E)
LEUKEMIA - A DISEASE OF THE BONE MARROW
-- A Prelude to Acute Myeloid Leukemia (AML)
-- Acute Myeloid Leukemia: Epidemiology
-- Acute Myeloid Leukemia (AML) Types
-- The FAB Classification of AML
-- WHO AML Classification
-- Etiology of AML
-- AML Symptoms
GLOBAL MARKET OUTLOOK AND PROSPECTS
-- Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive
Growth with Rising Patient Count & Promising Research Efforts
-- Drug Development Efforts Set Pace for Global Market
-- New Therapies Introduced in the Landscape
RECENT LAUNCHES IN THE AML MARKET
-- North America Maintains Leadership Position in Global Market
-- Chemotherapy: The Standard Mode of Treatment for AML Over the Years
-- Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to
Drive the Market
-- FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia
Therapeutics Market
-- Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years
2020 through 2027
EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA
-- Chemotherapy
-- AML Treatment
-- Stem Cell Transplant for Acute Myeloid Leukemia (AML)
-- Targeted Therapies Drive the Future of AML Market
ISOCITRATE DEHYDROGENASES (IDH)
-- BCL-2 Inhibitor
-- FLT3
-- Hedgehog (Hh)
-- Immunotherapy-Oriented Treatments
-- Neurotransmitter Receptors
-- Epigenetic Modulators
-- Organelle-Directed Strategies
-- New Formulations Using Existing Options
-- Antibody-Drug Conjugate Therapy for Acute Leukemia
-- Competitive Environment of AML Market
FOCUS ON SELECT PLAYERS (Total 112 Featured)
-- Amgen, Inc.
-- Astellas Pharma, Inc.
-- AbbVie, Inc.
-- A. Menarini Industrie Farmaceutiche Riunite Srl
-- Actinium Pharmaceuticals, Inc.
-- Aptose Biosciences, Inc.
-- Aprea Therapeutics
-- Astex Pharmaceuticals, Inc.
-- AB Science SA
-- Aptevo Therapeutics
-- Ascentage Pharma
-- arGEN-X
-- Accent Therapeutics
-- Arcellx
-- Amphivena Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/5may7s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-acute-myeloid-leukemia-aml-therapeutics-market-report-2023-2030-advancements-in-pharmacology--molecular-biology-to-promote-aml-drug-development-302007234.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
The Roadmap to Securing Your Own Digital Domain is Now Available | Jan 22, 2026
|
|
|
